Evidence map›Paper›PMID 31840206›Full record

ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2020

Effects of rivaroxaban on activated clotting time in catheter ablation for atrial fibrillation in Chinese patients.

Huang Songqun, Wang Chunling, Guo Zhifu, Huang Xinmiao, Cao Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  3. Article
  4. Article
  5. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huang SongqunDepartment of Cardiovasology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Wang ChunlingDepartment of Cardiovasology, The First People's Hospital of Baiyin, Gansu, 730900, China.
Guo ZhifuDepartment of Cardiovasology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China.
Huang XinmiaoDepartment of Cardiovasology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China. huangxinmiao@hotmail.com.
Cao JiangDepartment of Cardiovasology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433, China. chrfca@163.om.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIt has been observed that patients on rivaroxaban require more heparin and frequent activated clotting time (ACT) monitoring throughout the catheter ablation of atrial fibrillation, but the strategy of heparin injection varies in different studies. We sought to examine the determinants of heparin dosage in Chinese patients on rivaroxaban.

methodsWe reviewed consecutive patients who received rivaroxaban before atrial fibrillation ablation and compared them to patients on no anticoagulant. The dosage of heparin required to achieve ACT > 300 s was evaluated. We then tested determinants of heparin dosage prospectively.

resultsThere were 124 patients on rivaroxaban (R group) and 42 on no anticoagulant (NA group) in retrospective study. Heparin dosage required to achieve target ACT was 0.89 ± 0.01 mg/kg in R group and 0.60 ± 0.01 mg/kg in NA group, P < 0.05. The bolus heparin dosage required was 0.77 ± 0.01 mg/kg (96.1 ± 1.1 U/kg) when baseline ACT > 200 s. In the prospective study, 80/90(88.9%) of patients in R group and 79/90(87.8%) in NA group achieved an ACT > 300 s after initial bolus injection of heparin. The ACT 60 min after target ACT (ACT60) in R group was higher than that in NA group (287.5 ± 28.3 VS 238.9 ± 29.5, P < 0.05). Rivaroxaban was the only independent predictor of ACT60. There was no significant difference in ACT or heparin dosage in patients with different duration on or withdrawal of rivaroxaban.

conclusionsIn patients undergoing atrial fibrillation ablation on rivaroxaban, the effective duration of heparin is prolonged and the procedural heparin requirement is significantly greater. Heparin dosage can be predicted by baseline ACT, but not influenced by duration on or withdrawal of rivaroxaban.

Indexed as

Atrial FibrillationCatheter AblationAnticoagulantsChinaHumansProspective StudiesRetrospective StudiesRivaroxabanTreatment OutcomeAnticoagulantsRivaroxabanActivated clotting timeAtrial fibrillationCatheter ablationHeparinRivaroxaban

Identifiers

PMID31840206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.